Keywords: Genzyme, Sanofi-Aventis, M&A, Company value, Alemtuzumab

Genzyme argues case for higher valuation than Sanofi-Aventis ‘hostile offer, saying it is worth $89 a share

Article | 25 October 2010

Print This

US biotech major Genzyme (Nasdaq: GENZ) argued strongly that it is worth a lot more than the $69/share, or $18.5 billion, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in